The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | What is the most effective method for detecting circulating tumor cells in multiple myeloma?
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the most effective method for detecting circulating tumor cells (CTCs) in multiple myeloma. Dr Paiva highlights that flow cytometry is a powerful tool for monitoring CTCs in the peripheral blood, with strong prognostic value in smoldering and newly diagnosed myeloma. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, everyone knows I’m sort of biased towards flow cytometry. I do believe that flow cytometry is a method that is available in many, many hospitals around the world. Nowadays, the implementation of EuroFlow NGF is very high, again across the globe. And I think that we can benefit from having one assay, two applications. So one assay, NGF, two applications, MRD assessment as in the past, in the marrow and nowadays also circulating tumor cells in the peripheral blood...
Well, everyone knows I’m sort of biased towards flow cytometry. I do believe that flow cytometry is a method that is available in many, many hospitals around the world. Nowadays, the implementation of EuroFlow NGF is very high, again across the globe. And I think that we can benefit from having one assay, two applications. So one assay, NGF, two applications, MRD assessment as in the past, in the marrow and nowadays also circulating tumor cells in the peripheral blood. And I’d like to say that regarding the assessment of CTCs in the blood, I think that for staging of a precursor condition or a newly diagnosed myeloma patient, NGF with its 10 to the minus 6 sensitivity is more than enough and data is showing a very strong prognostic value. And what we have recently published was the development of a new method that we called blood flow that achieves much higher sensitivity, 10 to the minus 7. It combines immunomagnetic enrichment and then NGF and this strategy may be even more powerful at the stage of treatment or post-treatment to really identify those patients at risk of relapse after achieving an optimal response.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Bristol Myers Squibb/Celgene, Janssen, Sanofi, and Takeda: Consultancy; Adaptive, Amgen, Becton Dickinson, Bristol Myers Squibb/Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda: Honoraria; Aztra Zeneca, Bristol Myers Squibb/Celgene, EngMab, Roche, Sanofi, and Takeda: Research Funding.
